Literature DB >> 34031696

Apamin inhibits renal fibrosis via suppressing TGF-β1 and STAT3 signaling in vivo and in vitro.

Mi-Gyeong Gwon1, Hyun-Jin An1, Hyemin Gu1, Young-Ah Kim1, Sang Mi Han2, Kwan-Kyu Park3.   

Abstract

Renal fibrosis is a progressive and chronic process that influences kidneys with chronic kidney disease (CKD), irrespective of cause, leading to irreversible failure of renal function and end-stage kidney disease. Among the signaling related to renal fibrosis, transforming growth factor-β1 (TGF-β1) signaling is a major pathway that induces the activation of myofibroblasts and the production of extracellular matrix (ECM) molecules. Apamin, a component of bee venom (BV), has been studied in relation to various diseases. However, the effect of apamin on renal interstitial fibrosis has not been investigated. The aim of this study was to estimate the beneficial effect of apamin in unilateral ureteral obstruction (UUO)-induced renal fibrosis and TGF-β1-induced renal fibroblast activation. This study revealed that obstructive kidney injury induced an inflammatory response, tubular atrophy, and ECM accumulation. However, apamin treatment suppressed the increased expression of fibrotic-related genes, including α-SMA, vimentin, and fibronectin. Administration of apamin also attenuated the renal tubular cells injury and tubular atrophy. In addition, apamin attenuated fibroblast activation, ECM synthesis, and inflammatory cytokines such as TNF-α, IL-1β, and IL-6 by suppressing the TGF-β1-canonical and non-canonical signaling pathways. This study showed that apamin inhibits UUO-induced renal fibrosis in vivo and TGF-β1-induced renal fibroblasts activation in vitro. Apamin inhibited the inflammatory response, tubular atrophy, ECM accumulation, fibroblast activation, and renal interstitial fibrosis through suppression of TGF-β1/Smad2/3 and STAT3 signaling pathways. These results suggest that apamin might be a potential therapeutic agent for renal fibrosis. KEY MESSAGES: UUO injury can induce renal dysfunction; however, apamin administration prevents renal failure in UUO mice. Apamin inhibited renal inflammatory response and ECM deposition in UUO-injured mice. Apamin suppressed the activation of myofibroblasts in vivo and in vitro. Apamin has the anti-fibrotic effect on renal fibrosis via regulation of TGF-β1 canonical and non-canonical signaling.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Apamin; Myofibroblast; Renal fibrosis; STAT3; TGF-β1

Mesh:

Substances:

Year:  2021        PMID: 34031696     DOI: 10.1007/s00109-021-02087-x

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  55 in total

Review 1.  Signal transduction by the TGF-beta superfamily.

Authors:  Liliana Attisano; Jeffrey L Wrana
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

Review 2.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

Review 3.  Mechanisms of tubulointerstitial fibrosis.

Authors:  Michael Zeisberg; Eric G Neilson
Journal:  J Am Soc Nephrol       Date:  2010-09-23       Impact factor: 10.121

Review 4.  Inflammatory processes in renal fibrosis.

Authors:  Xiao-Ming Meng; David J Nikolic-Paterson; Hui Yao Lan
Journal:  Nat Rev Nephrol       Date:  2014-07-01       Impact factor: 28.314

5.  Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis.

Authors:  G Guo; J Morrissey; R McCracken; T Tolley; H Liapis; S Klahr
Journal:  Am J Physiol Renal Physiol       Date:  2001-05

6.  Ulinastatin attenuates renal interstitial inflammation and inhibits fibrosis progression in rats under unilateral ureteral obstruction.

Authors:  Guo-Tao Jiang; Xiao Chen; Dong Li; Hui-Xia An; Jun-Dong Jiao
Journal:  Mol Med Rep       Date:  2014-06-13       Impact factor: 2.952

Review 7.  Renal fibrosis: novel insights into mechanisms and therapeutic targets.

Authors:  Peter Boor; Tammo Ostendorf; Jürgen Floege
Journal:  Nat Rev Nephrol       Date:  2010-09-14       Impact factor: 28.314

Review 8.  Progression in chronic kidney disease.

Authors:  Allison A Eddy
Journal:  Adv Chronic Kidney Dis       Date:  2005-10       Impact factor: 3.620

Review 9.  Mechanisms of tubulointerstitial fibrosis.

Authors:  Masayuki Iwano; Eric G Neilson
Journal:  Curr Opin Nephrol Hypertens       Date:  2004-05       Impact factor: 2.894

10.  Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels.

Authors:  Ivica Grgic; Eva Kiss; Brajesh P Kaistha; Christoph Busch; Michael Kloss; Julia Sautter; Anja Müller; Anuradha Kaistha; Claudia Schmidt; Girija Raman; Heike Wulff; Frank Strutz; Hermann-Josef Gröne; Ralf Köhler; Joachim Hoyer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-13       Impact factor: 11.205

View more
  3 in total

Review 1.  Pharmacological effects and mechanisms of bee venom and its main components: Recent progress and perspective.

Authors:  Peiying Shi; Shihui Xie; Jiali Yang; Yi Zhang; Shuo Han; Songkun Su; Hong Yao
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

2.  NSC828779 Alleviates Renal Tubulointerstitial Lesions Involving Interleukin-36 Signaling in Mice.

Authors:  Shin-Ruen Yang; Szu-Chun Hung; Lichieh Julie Chu; Kuo-Feng Hua; Chyou-Wei Wei; I-Lin Tsai; Chih-Chin Kao; Chih-Chien Sung; Pauling Chu; Chung-Yao Wu; Ann Chen; Alexander T H Wu; Feng-Cheng Liu; Hsu-Shan Huang; Shuk-Man Ka
Journal:  Cells       Date:  2021-11-06       Impact factor: 6.600

3.  Therapeutic effect and mechanism of combination therapy with ursolic acid and insulin on diabetic nephropathy in a type I diabetic rat model.

Authors:  Yang Liu; Jin-Yan Zheng; Zhi-Tao Wei; Shu-Kun Liu; Ji-Lei Sun; Yin-Hui Mao; Yong-De Xu; Yong Yang
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.